Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TYRO3

TYRO3

Brief Information

Name:TYRO3 protein tyrosine kinase
Target Synonym:Tyrosine-Protein Kinase RSE,BYK,Tyrosine-Protein Kinase Receptor TYRO3,Tyrosine-Protein Kinase BYK,Etk-2,Rek,DTK,SKY,TIF,Brt,RSE,Tyrosine-protein kinase DTK,Tyrosine-protein kinase SKY,TYRO3,Tyrosine-protein kinase TIF,TYRO3 Protein Tyrosine Kinase
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TY3-H5251 Human Human TYRO3 / Dtk Protein, Fc Tag
TY3-H5251-structure
TY3-H5251-sds
ACRO Quality

Part of Bioactivity data

TY3-H5251-ELISA
 TYRO3 ELISA

Immobilized Human GAS6 Protein, His Tag (Cat. No. GA6-H5246) at 10 μg/mL (100 μL/well) can bind Human TYRO3, Fc Tag (Cat. No. TY3-H5251) with a linear range of 2.5-20 ng/mL (QC tested).

Synonym Name

TYRO3,BYK,DTK,RSE,SKY,TIF

Background

Tyrosine-protein kinase receptor TYRO3 is also known as Tyrosine-protein kinase BYK, DTK, RSE, SKY, TIF, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. TYRO3 regulates many physiological processes including cell survival, migration and differentiation. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 interacts (via N-terminus) with extracellular ligands TULP1 and GAS6 By similarity and also interacts with PIK3R1, this interaction increases PI3-kinase activity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate XL-184; BMS-907351; RO7047650; RO-7047650 Approved Exelixis Inc Cometriq, Cabometyx United States Thyroid Neoplasms; Carcinoma, Neuroendocrine Exelixis Inc 2012-11-29 Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Insulin transdermal (Phosphagenics) TPM-02 Phase 2 Clinical Phosphagenics Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Primary Ovarian Insufficiency Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message